{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:00Z","timestamp":1790504580152,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2017YFC1308604"],"award-info":[{"award-number":["2017YFC1308604"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81872446"],"award-info":[{"award-number":["81872446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovation program of science and research from the DICP, CAS","award":["DICP TMSR201601"],"award-info":[{"award-number":["DICP TMSR201601"]}]},{"name":"The strategic priority Research of the Chinese Academy of Scienices","award":["SDA16020900"],"award-info":[{"award-number":["SDA16020900"]}]},{"name":"The 100 Talents Programe of Chinese Academy of Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1082-6","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T15:04:05Z","timestamp":1550243045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC"],"prefix":"10.1186","volume":"38","author":[{"given":"Yalei","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingju","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"issue":"4","key":"1082_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"1082_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1082_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","volume":"367","author":"J Chen","year":"2015","unstructured":"Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015;367(1):1\u201311.","journal-title":"Cancer Lett"},{"issue":"6","key":"1082_CR4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/hep.28117","volume":"62","author":"DX Guan","year":"2015","unstructured":"Guan DX, Shi J, Zhang Y, Zhao JS, Long LY, Chen TW, Zhang EB, Feng YY, Bao WD, Deng YZ, et al. Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology. 2015;62(6):1791\u2013803.","journal-title":"Hepatology"},{"issue":"8","key":"1082_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/liv.12778","volume":"35","author":"FV Negri","year":"2015","unstructured":"Negri FV, Dal Bello B, Porta C, Campanini N, Rossi S, Tinelli C, Poggi G, Missale G, Fanello S, Salvagni S, et al. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver Int. 2015;35(8):2001\u20138.","journal-title":"Liver Int"},{"issue":"1","key":"1082_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/17474124.2017.1264874","volume":"11","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol. 2017;11(1):75\u201383.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7","key":"1082_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2174\/1389450117666151209120831","volume":"17","author":"G Mazzoccoli","year":"2016","unstructured":"Mazzoccoli G, Miele L, Oben J, Grieco A, Vinciguerra M. Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of Sorafenib. Curr Drug Targets. 2016;17(7):783\u201399.","journal-title":"Curr Drug Targets"},{"issue":"16","key":"1082_CR8","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","volume":"49","author":"J Bruix","year":"2013","unstructured":"Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49(16):3412\u20139.","journal-title":"Eur J Cancer"},{"key":"1082_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers10110412","volume":"10","author":"M Kudo","year":"2018","unstructured":"Kudo M. Systemic therapy for hepatocellular carcinoma: latest advances. Cancers (Basel). 2018;10:11.","journal-title":"Cancers (Basel)"},{"key":"1082_CR10","doi-asserted-by":"crossref","unstructured":"Bakouny Z, Assi T, El Rassy E, Nasr F. Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2018.","DOI":"10.1097\/MCG.0000000000001160"},{"key":"1082_CR11","unstructured":"Zhu AX: Recent developments in systemic therapy for hepatocellular carcinoma. Clin Adv Hematol Oncol 2017, 15 Suppl 9(8):7\u201313."},{"issue":"7","key":"1082_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","volume":"24","author":"M Inarrairaegui","year":"2018","unstructured":"Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res. 2018;24(7):1518\u201324.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1082_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin Liver Dis. 2018;38(4):379\u201388.","journal-title":"Semin Liver Dis"},{"key":"1082_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1741-7007-7-63","volume":"7","author":"T Stoelzle","year":"2009","unstructured":"Stoelzle T, Schwarb P, Trumpp A, Hynes NE. C-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol. 2009;7:63.","journal-title":"BMC Biol"},{"issue":"1","key":"1082_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56\u201367.","journal-title":"Cell"},{"issue":"1","key":"1082_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/excr.1999.4686","volume":"253","author":"CV Dang","year":"1999","unstructured":"Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. Function of the c-Myc oncogenic transcription factor. Exp Cell Res. 1999;253(1):63\u201377.","journal-title":"Exp Cell Res"},{"issue":"2","key":"1082_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000012024","volume":"57","author":"S Kawate","year":"1999","unstructured":"Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology. 1999;57(2):157\u201363.","journal-title":"Oncology"},{"issue":"12","key":"1082_CR18","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1096\/fasebj.6.12.1521738","volume":"6","author":"GJ Kato","year":"1992","unstructured":"Kato GJ, Dang CV. Function of the c-Myc oncoprotein. FASEB J. 1992;6(12):3065\u201372.","journal-title":"FASEB J"},{"issue":"1","key":"1082_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4254\/wjh.v2.i1.16","volume":"2","author":"CP Lin","year":"2010","unstructured":"Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010;2(1):16\u201320.","journal-title":"World J Hepatol"},{"issue":"12","key":"1082_CR20","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/MCB.01180-12","volume":"33","author":"MC Patel","year":"2013","unstructured":"Patel MC, Debrosse M, Smith M, Dey A, Huynh W, Sarai N, Heightman TD, Tamura T, Ozato K. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF\/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol Cell Biol. 2013;33(12):2497\u2013507.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1082_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2217\/epi.14.91","volume":"7","author":"M Jung","year":"2015","unstructured":"Jung M, Gelato KA, Fernandez-Montalvan A, Siegel S, Haendler B. Targeting BET bromodomains for cancer treatment. Epigenomics. 2015;7(3):487\u2013501.","journal-title":"Epigenomics"},{"key":"1082_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2017.01.031","volume":"391","author":"J Wang","year":"2017","unstructured":"Wang J, Wang Y, Mei H, Yin Z, Geng Y, Zhang T, Wu G, Lin Z. The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21. Cancer Lett. 2017;391:141\u201351.","journal-title":"Cancer Lett"},{"issue":"7","key":"1082_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/onc.2015.126","volume":"35","author":"PL Garcia","year":"2016","unstructured":"Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, Heslin MJ, Arnoletti JP, Richardson JH, Chen D, et al. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene. 2016;35(7):833\u201345.","journal-title":"Oncogene"},{"issue":"7327","key":"1082_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"2","key":"1082_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1158\/0008-5472.CAN-17-2040","volume":"78","author":"S Mustafi","year":"2018","unstructured":"Mustafi S, Camarena V, Volmar CH, Huff TC, Sant DW, Brothers SP, Liu ZJ, Wahlestedt C, Wang G. Vitamin C Sensitizes Melanoma to BET Inhibitors. Cancer Res. 2018;78(2):572\u201383.","journal-title":"Cancer Res"},{"issue":"5","key":"1082_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","volume":"16","author":"AM Kurimchak","year":"2016","unstructured":"Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, et al. Resistance to BET Bromodomain inhibitors is mediated by Kinome reprogramming in ovarian Cancer. Cell Rep. 2016;16(5):1273\u201386.","journal-title":"Cell Rep"},{"issue":"22","key":"1082_CR27","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1158\/1078-0432.CCR-12-3904","volume":"19","author":"T Shimamura","year":"2013","unstructured":"Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res. 2013;19(22):6183\u201392.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1082_CR28","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ijc.29269","volume":"136","author":"DH Lee","year":"2015","unstructured":"Lee DH, Qi J, Bradner JE, Said JW, Doan NB, Forscher C, Yang H, Koeffler HP. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer. 2015;136(9):2055\u201364.","journal-title":"Int J Cancer"},{"issue":"8","key":"1082_CR29","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","volume":"23","author":"YF Ma","year":"2017","unstructured":"Ma YF, Wang LH, Neitzel LR, Loganathan SN, Tang N, Qin LL, Crispi EE, Guo Y, Knapp S, Beauchamp RD, et al. The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal Cancer. Clin Cancer Res. 2017;23(8):2027\u201337.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1082_CR30","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.18632\/oncotarget.6275","volume":"7","author":"GQ Li","year":"2016","unstructured":"Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP, Ma XX, Zhang G, Li J, Yan B, Tang HW, et al. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget. 2016;7(3):2462\u201374.","journal-title":"Oncotarget"},{"issue":"9","key":"1082_CR31","doi-asserted-by":"publisher","first-page":"e74250","DOI":"10.1371\/journal.pone.0074250","volume":"8","author":"R Aguirre-Gamboa","year":"2013","unstructured":"Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Pena JG, Trevino V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013;8(9):e74250.","journal-title":"PLoS One"},{"issue":"17","key":"1082_CR32","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-15-2274","volume":"22","author":"K Tateishi","year":"2016","unstructured":"Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor TT, Flaherty KT, Onozato ML, Lelic N, Sundaram S, Cahill DP, et al. Myc-driven glycolysis is a therapeutic target in glioblastoma. Clin Cancer Res. 2016;22(17):4452\u201365.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1082_CR33","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/pmic.200300653","volume":"4","author":"SJ Ding","year":"2004","unstructured":"Ding SJ, Li Y, Shao XX, Zhou H, Zeng R, Tang ZY, Xia QC. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics. 2004;4(4):982\u201394.","journal-title":"Proteomics"},{"issue":"5","key":"1082_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/cr.2015.30","volume":"25","author":"S Ji","year":"2015","unstructured":"Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H, Gao J, Zhang B, Xu W, Liu J, et al. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015;25(5):561\u201373.","journal-title":"Cell Res"},{"key":"1082_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.pharmtox.48.113006.094649","volume":"50","author":"V Gonzalez","year":"2010","unstructured":"Gonzalez V, Hurley LH. The c-MYC NHE III(1): function and regulation. Annu Rev Pharmacol Toxicol. 2010;50:111\u201329.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"1082_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell"},{"issue":"9","key":"1082_CR37","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.18632\/oncotarget.3126","volume":"6","author":"HF Qiu","year":"2015","unstructured":"Qiu HF, Jackson AL, Kilgore JE, Zhong Y, Chang LLY, Gehrig PA, Zhou CX, Bae-Jump VL. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. Oncotarget. 2015;6(9):6915\u201330.","journal-title":"Oncotarget"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1082-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T22:28:25Z","timestamp":1606516105000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1082-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1082-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"17 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of the Dalian Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"83"}}